Pretreatment neutrophil‐lymphocyte ratio is not a significant prognostic factor in epidermal growth factor receptor‐mutant non‐small cell lung cancer patients treated with tyrosine kinase inhibitors
Authors:
Open Access
- 28 August 2015
- journal article
- Published by Wiley in Thoracic Cancer
- Vol. 7 (2) , 161-166
Abstract
The neutrophil‐lymphocyte ratio (NLR) is a marker of poor prognosis in lung cancer patients. However, previous data have been based on an heterogeneous population of lung cancer patients and various treatments. In this study, we evaluate the prognostic value of NLR in an homogeneous population of epidermal growth factor receptor (EGFR)‐mutant non‐small cell lung cancer (NSCLC) patients. We restrospectively evaluated the data of 250 NSCLC patients with EGFR mutations. All data are based on first‐line treatment. All tumors harbored in‐frame deletions in exon 19 or an L858R point mutation. Eighty‐five patients were treated with tyrosine kinase inhibitors (TKIs), while 165 received cytotoxic chemotherapy as first‐line treatment. Multivariate survival analysis revealed that the NLR was a significant prognostic factor for first‐line progression‐free survival (PFS) in the chemotherapy group (hazard ratio [HR] 1.882, 95% confidence interval [CI] 1.319–2.686, P = 0.001), but was not significant in the TKI group (HR 1.239, 95% CI 0.693–2.215, P = 0.469). The response rate (RR) to first‐line treatment was 76.5% in the TKI group and 29.5% in the chemotherapy group; however, the RR, according to the NLR (≤3 vs. > 3), was the same for both groups. The NLR was a significant prognostic factor in the chemotherapy group, but it did not affect either RR or PFS in EGFR‐mutant NSCLC patients treated with TKIs.Keywords
Funding Information
- Innovative Research Institute for Cell Therapy, Republic of Korea (A062260)
This publication has 18 references indexed in Scilit:
- The systemic inflammation-based neutrophil–lymphocyte ratio: Experience in patients with cancerCritical Reviews in Oncology/Hematology, 2013
- Pretreatment neutrophil to lymphocyte ratio is associated with response to therapy and prognosis of advanced non-small cell lung cancer patients treated with first-line platinum-based chemotherapyCancer Immunology, Immunotherapy, 2012
- Early neutrophil-to-lymphocyte ratio reduction as a surrogate marker of prognosis in never smokers with advanced lung adenocarcinoma receiving gefitinib or standard chemotherapy as first-line therapyJournal of Cancer Research and Clinical Oncology, 2012
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in CancerNew England Journal of Medicine, 2012
- Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFRNew England Journal of Medicine, 2010
- Pretreatment neutrophil count as an independent prognostic factor in advanced non-small-cell lung cancer: An analysis of Japan Multinational Trial Organisation LC00-03European Journal of Cancer, 2009
- Cancer-related inflammationNature, 2008
- Immune surveillance of tumorsJournal of Clinical Investigation, 2007
- A prognostic model for advanced stage nonsmall cell lung cancerCancer, 2006
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI: Journal of the National Cancer Institute, 2000